Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DnaJ heat shock protein family (Hsp40) member C27 (DNAJC27) is a member of the Hsp40/DnaJ co-chaperone families, predicted to function as a small Ras-like GTPase. It is involved in intracellular protein transport and is located in the cytoplasm, cytoplasmic vesicles, and nucleus[1][2][6][7]. DNAJC27 has been shown to activate the MEK/ERK pathway, potentially by serving as a nuclear scaffold for MAPK1/ERK2, thus enhancing ERK signaling and influencing cell transformation when overexpressed[2][3]. Genome-wide association studies indicate that variants in or near DNAJC27 are linked to variation in human body mass index, supporting a role in energy metabolism and obesity susceptibility[1]. Elevated circulating DNAJC27 is seen in obese individuals and patients with type 2 diabetes, suggesting a possible contributory role in these metabolic diseases[1]. There is no current evidence that DNAJC27 is a direct therapeutic target or druggable protein, but its function at the interface of stress response and metabolism makes it of interest for further research into metabolic and stress-related diseases[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DnaJ heat shock protein family (Hsp40) member C27 (DNAJC27).